MHLW Requires Expert Panel Members To Disclose Special Interests With Makers
This article was originally published in PharmAsia News
Executive Summary
The Advanced Medical Technology Advisory Committee at the Ministry of Health, Labor and Welfare June 17 decided on new rules requiring expert panel members to disclose financial ties with drug or device makers whose products are under review. It ruled that if members or their relatives have received more than ¥5 million in donations or contract payments in the past three years, they should not attend review meetings for the drugs or devices. If the amount is between ¥5 million and ¥500,000, the member is allowed to attend discussion sessions, and below ¥500,000, he or she will be able to attend final summary sessions. MHLW defines the payments as consulting and instruction fees on patent and trademarks, speech fees and authoring compensations. The Ministry asks advisory board members and relatives to self claim the maximum amount received (Click here for more - Japanese language